Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a ChRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a ChRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.
加利福尼亞州伯克利，2024年4月15日（GLOBE NEWSWIRE）——臨床階段領先的CRISPR基因組編輯生物製藥公司Caribou Biosciences, Inc.（納斯達克股票代碼：CRBU）今天宣佈了一份關於有效使用Cas12a chrDNA基因組編輯技術的摘要 在活體中 肝臟基因干擾已獲准在27日的口頭陳述第四 美國基因與細胞療法學會（ASGCT）年會將於2024年5月7日至11日在馬里蘭州巴爾的摩舉行。
Details of the oral presentation are as follows:
口頭陳述的詳情如下：
Title: Cas12a CRISPR hybrid RNA-DNA (chRDNA)-mediated in vivo genome-editing technology for efficient and functional hepatic gene disruption
Presenter: Meghdad Rahdar, PhD, director of technology development, Caribou Biosciences
Date and time: Friday, May 10, 2024 at 4:30 pm ET
Session: Advancements in Technologies for In Vivo Gene Therapies
Location: 324-326
Abstract number: 278
標題：Cas12a CRISPR 混合 RNA-DNA (chrDNA) 介導 在活體中 基因組編輯技術可實現高效和功能性的肝基因破壞
演講者：邁格達德·拉赫達爾博士，Caribou Biosciences技術開發總監
日期和時間：美國東部時間 2024 年 5 月 10 日星期五下午 4:30
會議：以下領域的技術進步 在Vivo 基因療法
地點：324-326
摘要編號：278
Accepted abstracts will be available on the ASGCT Annual Meeting website on April 22, 2024 at 4:30 pm ET. The presentation will be available on the Scientific Publications page of Caribou's website on Friday, May 10, 2024 at 6:00 am ET.
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
關於 Caribou 的新型下一代 CRISPR 平台
CRISPR 基因組編輯使用易於設計的模塊化生物學工具對活細胞進行 DNA 更改。2 類 CRISPR 系統有兩個基本組成部分：切割 DNA 的核酸酶蛋白和引導核酸酶產生位點特異性雙鏈斷裂、導致目標基因組位點編輯的 RNA 分子。CRISPR系統能夠編輯意想不到的基因組位點，即脫靶編輯，這可能會對細胞功能和表型造成有害影響。爲了應對這一挑戰，Caribou開發了CRISPR混合RNA-DNA指南（chrDNA；發音爲 “chardonnays”），與全RNA指南相比，它指導的基因組編輯要精確得多。Caribou正在利用其chrDNA技術的力量進行高效的多次編輯，開發經過CRISPR編輯的療法。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of clinical-stage off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
關於 Caribou Biosciences, Inc.
Caribou Biosciences是一家臨床階段的CRISPR基因組編輯生物製藥公司，致力於爲患有毀滅性疾病的患者開發變革性療法。該公司的基因組編輯平台，包括其Cas12a chrDNA技術，能夠以卓越的精度開發具有潛在改善疾病活性的細胞療法。Caribou正在從其CAR-T細胞平台推進臨床階段的現成細胞療法產品線，這些療法是血液系統惡性腫瘤和自身免疫性疾病患者的現成治療方法。關注我們 @CaribouBio 然後訪問 www.cariboubio.com。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou 生物科學公司聯繫方式：
投資者：
艾米·菲格羅亞，CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒體：
Peggy Vorwald，博士
media@cariboubio.com
譯文內容由第三人軟體翻譯。